Autoreactive-Aβ antibodies promote APP β-secretase processing

Journal of Neurochemistry

Volumn 120, Issue 5, 2012, Pages 732-740

  Deng, Juan ^a,b   Hou, Huayan ^a   Giunta, Brian ^a,f   Mori, Takashi ^c   Wang, Yan Jiang ^b   Fernandez, Frank ^a   Weggen, Sascha ^d   Araki, Wataru ^e   Obregon, Demian ^a,f   Tan, Jun ^a,f  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

A 40,42 peptides; Alzheimer's disease; anti N terminal A antibodies; APP amyloidogenic processing; auto A antibodies

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-17]; AMYLOID BETA PROTEIN[1-17] ANTIBODY; AMYLOID PRECURSOR PROTEIN; AUTOANTIBODY; BETA SECRETASE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHO CELL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; PROTEIN TARGETING; UPREGULATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; AUTOANTIBODIES; CELL LINE; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MIDDLE AGED;

EID: 84862778010     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07629.x     Document Type: Article

References (35)

1. Bacher M., Depboylu C., Du Y., Noelker C., Oertel W. H., Behr T., Henriksen G., Behe M., and, Dodel R., (2009) Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. Neurosci. Lett. 449, 240-245.
2. Bei R., Masuelli L., Palumbo C., Modesti M., and, Modesti A., (2009) A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth. Cancer Lett. 281, 8-23.
3. Britschgi M., Olin C. E., Johns H. T., et al. (2009) Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc. Natl. Acad. Sci. USA 106, 12145-12150.
4. Cleary J. P., Walsh D. M., Hofmeister J. J., Shankar G. M., Kuskowski M. A., Selkoe D. J., and, Ashe K. H., (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8, 79-84.
5. DeMattos R. B., Bales K. R., Cummins D. J., Dodart J. C., Paul S. M., and, Holtzman D. M., (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98, 8850-8855.
6. Dodel R. C., Du Y., Depboylu C., et al. (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472-1474.
7. Du Y., Dodel R., Hampel H., et al. (2001) Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 57, 801-805.
8. Giunta B., Obregon D., Hou H., et al. (2006) EGCG mitigates neurotoxicity mediated by HIV-1 proteins gp120 and Tat in the presence of IFN-gamma: role of JAK/STAT1 signaling and implications for HIV-associated dementia. Brain Res. 1123, 216-225.
9. Glabe C. G., (2008) Structural classification of toxic amyloid oligomers. J. Biol. Chem. 283, 29639-29643.
10. Haass C., and, Selkoe D. J., (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112.
11. Hahn S., Bruning T., Ness J., et al. (2011) Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to gamma-secretase modulators regardless of their potency and structure. J. Neurochem. 116, 385-395.
12. Holmes C., Boche D., Wilkinson D., et al. (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216-223.
13. Jankowsky J. L., Slunt H. H., Ratovitski T., Jenkins N. A., Copeland N. G., and, Borchelt D. R., (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 17, 157-165.
14. Khandogin J., and, Brooks C. L. 3rd, (2007) Linking folding with aggregation in Alzheimer's beta-amyloid peptides. Proc. Natl. Acad. Sci. USA 104, 16880-16885.
15. Klyubin I., Walsh D. M., Lemere C. A., et al. (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11, 556-561.
16. Lee M., Bard F., Johnson-Wood K., Lee C., Hu K., Griffith S. G., Black R. S., Schenk D., and, Seubert P., (2005) Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann. Neurol. 58, 430-435.
17. Lesne S., Koh M. T., Kotilinek L., Kayed R., Glabe C. G., Yang A., Gallagher M., and, Ashe K. H., (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
18. Mamikonyan G., Necula M., Mkrtichyan M., et al. (2007) Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J. Biol. Chem. 282, 22376-22386.
19. Monsonego A., Zota V., Karni A., et al. (2003) Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112, 415-422.
20. Morgan D., (2011) Immunotherapy for Alzheimer's disease. J. Intern. Med. 269, 54-63.
21. Morgan D., Diamond D. M., Gottschall P. E., et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985.
22. Orgogozo J. M., Gilman S., Dartigues J. F., et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 46-54.
23. Pride M., Seubert P., Grundman M., Hagen M., Eldridge J., and, Black R. S., (2008) Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener. Dis. 5, 194-196.
24. Rezai-Zadeh K., Shytle D., Sun N., et al. (2005) Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 25, 8807-8814.
25. Schenk D., Barbour R., Dunn W., et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
26. Selkoe D. J., (2004) Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell Biol. 6, 1054-1061.
27. Shankar G. M., Li S., Mehta T. H., et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842.
28. Shoenfeld Y., Cervera R., Haass M., Kallenberg C., Khamashta M., Meroni P., Piette J. C., Schmidt R., and, Wiik A., (2007) EASI-The European Autoimmunity Standardisation Initiative: a new initiative that can contribute to agreed diagnostic models of diagnosing autoimmune disorders throughout Europe. Ann. N Y Acad. Sci. 1109, 138-144.
29. Taguchi H., Planque S., Nishiyama Y., et al. (2008) Autoantibody- catalyzed hydrolysis of amyloid beta peptide. J. Biol. Chem. 283, 4714-4722.
30. Tan J., Town T., Crawford F., Mori T., DelleDonne A., Crescentini R., Obregon D., Flavell R. A., and, Mullan M. J., (2002) Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat. Neurosci. 5, 1288-1293.
31. Tomic J. L., Pensalfini A., Head E., and, Glabe C. G., (2009) Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol. Dis. 35, 352-358.
32. Townsend M., Shankar G. M., Mehta T., Walsh D. M., and, Selkoe D. J., (2006) Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 572, 477-492.
33. Walsh D. M., Klyubin I., Fadeeva J. V., Cullen W. K., Anwyl R., Wolfe M. S., Rowan M. J., and, Selkoe D. J., (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
34. Weggen S., Eriksen J. L., Sagi S. A., Pietrzik C. U., Golde T. E., and, Koo E. H., (2003) Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J. Biol. Chem. 278, 30748-30754.
35. Weksler M. E., Relkin N., Turkenich R., LaRusse S., Zhou L., and, Szabo P., (2002) Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 37, 943-948.